Upgrades Archives - Page 149 of 188

1 minute read

Piper Sandler Upgrades e.l.f. Beauty to Overweight, Raises Price Target to $46

October 11, 6:52 AM

Piper Sandler analyst Korinne Wolfmeyer upgrades e.l.f. Beauty (NYSE:ELF) from Neutral to Overweight and raises the price target from $35 to $46.

ELF

1 minute read

SVB Leerink Upgrades scPharmaceuticals to Outperform, Raises Price Target to $11

By Benzinga Newsdesk

October 11, 6:08 AM

SVB Leerink analyst Roanna Ruiz upgrades scPharmaceuticals (NASDAQ:SCPH) from Market Perform to Outperform and raises the price target from $6 to $11.

SCPH

1 minute read

Toast Gets An Upgrade As Industry Survey Exudes Promise

By Anusuya Lahiri

October 10, 12:31 PM

Mizuho analyst Dan Dolev upgraded Toast, Inc (NYSE:TOST) from Neutral to Buy and raised the price target from $22 to $24. Mizuho’s…

TOST

2 minute read

Kraft Heinz Analyst Projects Gross Margin Inflection Ahead, Says Company Now Structurally Better Positioned

By Priya Nigam

October 10, 10:41 AM

While Kraft Heinz Co (NASDAQ: KHC) is well positioned to benefit from improving market dynamics and is among the few Consumer Staples stocks that do not already reflect the potential upside, according to Goldman Sachs.

KHC

1 minute read

OTR Global Upgrades Restaurant Brands Intl to Positive

By Benzinga Newsdesk

October 10, 9:54 AM

OTR Global upgrades Restaurant Brands Intl (NYSE:QSR) from Mixed to Positive.

QSR

1 minute read

Morgan Stanley Upgrades Fortinet to Overweight, Raises Price Target to $69

By Benzinga Newsdesk

October 10, 9:46 AM

Morgan Stanley analyst Hamza Fodderwala upgrades Fortinet (NASDAQ:FTNT) from Equal-Weight to Overweight and raises the price target from $66 to $69.

FTNT

1 minute read

Mizuho Upgrades Toast to Buy, Raises Price Target to $24

By Benzinga Newsdesk

October 10, 7:04 AM

Mizuho analyst Dan Dolev upgrades Toast (NYSE:TOST) from Neutral to Buy and raises the price target from $22 to $24.

TOST

1 minute read

SVB Leerink Upgrades Satsuma Pharmaceuticals to Outperform, Raises Price Target to $15

By Benzinga Newsdesk

October 10, 6:58 AM

SVB Leerink analyst Marc Goodman upgrades Satsuma Pharmaceuticals (NASDAQ:STSA) from Market Perform to Outperform and raises the price target from $5 to $15.

STSA